Country data on AMR in Türkiye in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action. To review AMR in Türkiye and initiatives addressing it. Identifying any areas where more information is required will provide a call to action to minimize any further rise in AMR within Türkiye and to improve patient outcomes. National AMR initiatives, antibiotic use and prescribing, and availability of susceptibility data, particularly for the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines commonly used locally for specific CA-RTIs (community-acquired pneumonia, acute otitis media, acute bacterial rhinosinusitis) were also reviewed, plus local antibiotic availability. Insights from both a local clinician and local clinical microbiologist were sought to contextualize this information. Türkiye developed an antibiotic stewardship programme, The Rational Drug Use National Action Plan 2014-2017, prioritizing appropriate antibiotic prescription in the community. Public campaigns discouraging inappropriate antibiotic use were also initiated. Türkiye has a high level of antibiotic resistance and a high level of consumption, however, in 2015 over-the-counter antibiotic sales were prohibited, resulting in a declining trend in overall consumption. There is still a need for physician education on current developments in antibiotic use. Several ongoing global surveillance studies provide antibiotic susceptibility data in Türkiye. Clinicians in Türkiye use several country-specific guidelines for common CA-RTIs plus a range of international guidelines. A more standardized inclusive approach in developing local guidelines, using up-to-date surveillance data on isolates from community-acquired infections in Türkiye, could make guideline use more relevant for clinicians. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development and improve patient outcome.
Sections du résumé
BACKGROUND
Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action.
OBJECTIVES
To review AMR in Türkiye and initiatives addressing it. Identifying any areas where more information is required will provide a call to action to minimize any further rise in AMR within Türkiye and to improve patient outcomes.
METHODS
National AMR initiatives, antibiotic use and prescribing, and availability of susceptibility data, particularly for the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines commonly used locally for specific CA-RTIs (community-acquired pneumonia, acute otitis media, acute bacterial rhinosinusitis) were also reviewed, plus local antibiotic availability. Insights from both a local clinician and local clinical microbiologist were sought to contextualize this information.
CONCLUSIONS
Türkiye developed an antibiotic stewardship programme, The Rational Drug Use National Action Plan 2014-2017, prioritizing appropriate antibiotic prescription in the community. Public campaigns discouraging inappropriate antibiotic use were also initiated. Türkiye has a high level of antibiotic resistance and a high level of consumption, however, in 2015 over-the-counter antibiotic sales were prohibited, resulting in a declining trend in overall consumption. There is still a need for physician education on current developments in antibiotic use. Several ongoing global surveillance studies provide antibiotic susceptibility data in Türkiye. Clinicians in Türkiye use several country-specific guidelines for common CA-RTIs plus a range of international guidelines. A more standardized inclusive approach in developing local guidelines, using up-to-date surveillance data on isolates from community-acquired infections in Türkiye, could make guideline use more relevant for clinicians. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development and improve patient outcome.
Identifiants
pubmed: 36065733
pii: 6692272
doi: 10.1093/jac/dkac217
pmc: PMC9445858
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
i51-i60Subventions
Organisme : GlaxoSmithKline
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
J Antimicrob Chemother. 2022 Sep 6;77(Supplement_1):i2-i9
pubmed: 36065724
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
Am Fam Physician. 2013 Oct 1;88(7):435-40
pubmed: 24134083
Euro Surveill. 2015 May 28;20(21):
pubmed: 26062562
J Antimicrob Chemother. 2002 Jan;49(1):31-40
pubmed: 11751764
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Pediatrics. 2013 Jul;132(1):e262-80
pubmed: 23796742
J Antimicrob Chemother. 2020 Apr 1;75(Suppl 1):i88-i99
pubmed: 32337598
Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1242-1249
pubmed: 34155708
Infect Drug Resist. 2021 Jul 05;14:2557-2568
pubmed: 34262300
Otolaryngol Head Neck Surg. 2015 Apr;152(2 Suppl):S1-S39
pubmed: 25832968
BMJ. 2018 Nov 12;363:k3047
pubmed: 30420401
J Antimicrob Chemother. 2016 May;71 Suppl 1:i71-83
pubmed: 27048584
J Antimicrob Chemother. 2016 May;71 Suppl 1:i85-91
pubmed: 27048585
Glob Health Med. 2019 Dec 31;1(2):61-64
pubmed: 33330756
Clin Microbiol Infect. 2019 Jun;25(6):651-653
pubmed: 30844434
Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents
pubmed: 17630331
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
Clin Infect Dis. 2012 Apr;54(8):e72-e112
pubmed: 22438350
Thorax. 2011 Oct;66 Suppl 2:ii1-23
pubmed: 21903691
Clin Microbiol Infect. 2019 Jul;25(7):910-911
pubmed: 30910717
Pediatrics. 2013 Mar;131(3):e964-99
pubmed: 23439909
Thorax. 2009 Oct;64 Suppl 3:iii1-55
pubmed: 19783532
Clin Infect Dis. 2011 Oct;53(7):e25-76
pubmed: 21880587